Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
Lithium increases mitochondrial respiration in iPSC-derived neural precursor cells from lithium responders
The physical and mental burden of dry eye disease: A large population-based study investigating the relationship with health-related quality of life and its determinants
Ocul Surf, 21, 107-117 (in press)
Geriatric Assessment and Management in Cancer
J Clin Oncol, JCO2100089 (in press)